Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 167

Similar articles for PubMed (Select 22689910)

1.

Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy.

Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M.

Brain. 2012 Jul;135(Pt 7):2169-77. doi: 10.1093/brain/aws143. Epub 2012 Jun 10.

2.

Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation.

Rodríguez-Navarro JA, Rodríguez L, Casarejos MJ, Solano RM, Gómez A, Perucho J, Cuervo AM, García de Yébenes J, Mena MA.

Neurobiol Dis. 2010 Sep;39(3):423-38. doi: 10.1016/j.nbd.2010.05.014. Epub 2010 May 28.

PMID:
20546895
3.

Stimulation of autophagy is neuroprotective in a mouse model of human tauopathy.

Schaeffer V, Goedert M.

Autophagy. 2012 Nov;8(11):1686-7. doi: 10.4161/auto.21488. Epub 2012 Aug 9.

4.

Autophagic degradation of tau in primary neurons and its enhancement by trehalose.

Krüger U, Wang Y, Kumar S, Mandelkow EM.

Neurobiol Aging. 2012 Oct;33(10):2291-305. doi: 10.1016/j.neurobiolaging.2011.11.009. Epub 2011 Dec 14.

PMID:
22169203
5.

Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance.

Jiang T, Yu JT, Zhu XC, Zhang QQ, Cao L, Wang HF, Tan MS, Gao Q, Qin H, Zhang YD, Tan L.

Neuropharmacology. 2014 Oct;85:121-30. doi: 10.1016/j.neuropharm.2014.05.032. Epub 2014 May 29.

PMID:
24880087
6.

Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.

Ozcelik S, Fraser G, Castets P, Schaeffer V, Skachokova Z, Breu K, Clavaguera F, Sinnreich M, Kappos L, Goedert M, Tolnay M, Winkler DT.

PLoS One. 2013 May 7;8(5):e62459. doi: 10.1371/journal.pone.0062459. Print 2013.

7.

Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice.

Leroy K, Bretteville A, Schindowski K, Gilissen E, Authelet M, De Decker R, Yilmaz Z, Buée L, Brion JP.

Am J Pathol. 2007 Sep;171(3):976-92. Epub 2007 Aug 9.

8.

A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.

Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, Behar L, Ben-Hur T, Avraham Y, Berry E, Segal M, Ginzburg I, Abramsky O.

Exp Neurol. 2008 Jul;212(1):71-84. doi: 10.1016/j.expneurol.2008.03.007. Epub 2008 Mar 21.

PMID:
18490011
9.

GSPE interferes with tau aggregation in vivo: implication for treating tauopathy.

Santa-Maria I, Diaz-Ruiz C, Ksiezak-Reding H, Chen A, Ho L, Wang J, Pasinetti GM.

Neurobiol Aging. 2012 Sep;33(9):2072-81. doi: 10.1016/j.neurobiolaging.2011.09.027. Epub 2011 Nov 4.

10.

Retarded axonal transport of R406W mutant tau in transgenic mice with a neurodegenerative tauopathy.

Zhang B, Higuchi M, Yoshiyama Y, Ishihara T, Forman MS, Martinez D, Joyce S, Trojanowski JQ, Lee VM.

J Neurosci. 2004 May 12;24(19):4657-67.

11.

Early behavioural markers of disease in P301S tau transgenic mice.

Scattoni ML, Gasparini L, Alleva E, Goedert M, Calamandrei G, Spillantini MG.

Behav Brain Res. 2010 Mar 17;208(1):250-7. doi: 10.1016/j.bbr.2009.12.002. Epub 2009 Dec 11.

PMID:
20004218
12.

Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.

Vega IE, Cui L, Propst JA, Hutton ML, Lee G, Yen SH.

Brain Res Mol Brain Res. 2005 Aug 18;138(2):135-44.

13.

Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.

Ando K, Leroy K, Héraud C, Yilmaz Z, Authelet M, Suain V, De Decker R, Brion JP.

Am J Pathol. 2011 Feb;178(2):803-16. doi: 10.1016/j.ajpath.2010.10.034.

14.

A novel calcium-binding protein is associated with tau proteins in tauopathy.

Vega IE, Traverso EE, Ferrer-Acosta Y, Matos E, Colon M, Gonzalez J, Dickson D, Hutton M, Lewis J, Yen SH.

J Neurochem. 2008 Jul;106(1):96-106. doi: 10.1111/j.1471-4159.2008.05339.x. Epub 2008 Jul 1.

15.

Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau.

Lin WL, Lewis J, Yen SH, Hutton M, Dickson DW.

J Neurocytol. 2003 Nov;32(9):1091-105.

PMID:
15044841
16.

Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy.

Delobel P, Lavenir I, Fraser G, Ingram E, Holzer M, Ghetti B, Spillantini MG, Crowther RA, Goedert M.

Am J Pathol. 2008 Jan;172(1):123-31. Epub 2007 Dec 13.

17.

Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: a system for screening drugs against tauopathies.

Mellone M, Kestoras D, Andrews MR, Dassie E, Crowther RA, Stokin GB, Tinsley J, Horne G, Goedert M, Tolkovsky AM, Spillantini MG.

J Neurosci. 2013 Nov 13;33(46):18175-89. doi: 10.1523/JNEUROSCI.4933-12.2013.

18.

Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion.

Shimada K, Motoi Y, Ishiguro K, Kambe T, Matsumoto SE, Itaya M, Kunichika M, Mori H, Shinohara A, Chiba M, Mizuno Y, Ueno T, Hattori N.

Neurobiol Dis. 2012 Apr;46(1):101-8. doi: 10.1016/j.nbd.2011.12.050. Epub 2012 Jan 10.

PMID:
22249108
19.

Transmission and spreading of tauopathy in transgenic mouse brain.

Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M.

Nat Cell Biol. 2009 Jul;11(7):909-13. doi: 10.1038/ncb1901. Epub 2009 Jun 7.

20.

Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies.

Falzone TL, Gunawardena S, McCleary D, Reis GF, Goldstein LS.

Hum Mol Genet. 2010 Nov 15;19(22):4399-408. doi: 10.1093/hmg/ddq363. Epub 2010 Sep 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk